Emerald Mutual Fund Advisers Trust Buys 76,074 Shares of Omnicell Inc. (OMCL)
Emerald Mutual Fund Advisers Trust raised its position in Omnicell Inc. (NASDAQ:OMCL) by 193.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,417 shares of the company’s stock after buying an additional 76,074 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Omnicell were worth $3,951,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of OMCL. Diversified Trust Co purchased a new position in Omnicell during the second quarter valued at about $216,000. Eqis Capital Management Inc. raised its position in Omnicell by 11.9% in the second quarter. Eqis Capital Management Inc. now owns 9,163 shares of the company’s stock valued at $314,000 after buying an additional 971 shares in the last quarter. Bank of Montreal Can purchased a new position in Omnicell during the second quarter valued at about $322,000. Menta Capital LLC purchased a new position in Omnicell during the first quarter valued at about $332,000. Finally, Aperio Group LLC raised its position in Omnicell by 10.9% in the first quarter. Aperio Group LLC now owns 13,132 shares of the company’s stock valued at $366,000 after buying an additional 1,288 shares in the last quarter. 95.26% of the stock is owned by institutional investors.
Omnicell Inc. (NASDAQ:OMCL) traded down 0.30% on Friday, reaching $36.79. 165,963 shares of the company were exchanged. Omnicell Inc. has a 52 week low of $25.06 and a 52 week high of $40.50. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of 93.38 and a beta of 0.58. The stock has a 50-day moving average price of $37.88 and a 200 day moving average price of $33.96.
Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.06. The company had revenue of $175.60 million for the quarter, compared to analyst estimates of $170.89 million. Omnicell had a net margin of 2.36% and a return on equity of 10.41%. The firm’s quarterly revenue was up 55.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.28 EPS. Analysts forecast that Omnicell Inc. will post $1.58 earnings per share for the current year.
Several equities analysts have issued reports on OMCL shares. FBR & Co lifted their price target on shares of Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 7th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $46.00 price target on shares of Omnicell in a report on Tuesday, September 13th. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Wednesday, June 29th. Finally, Sidoti lowered shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price target on the stock. in a report on Thursday, September 8th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Omnicell has an average rating of “Buy” and a consensus target price of $38.13.
In other news, Director Gary S. Petersmeyer sold 2,000 shares of the firm’s stock in a transaction on Monday, September 12th. The shares were sold at an average price of $37.98, for a total value of $75,960.00. Following the sale, the director now directly owns 17,987 shares in the company, valued at approximately $683,146.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary S. Petersmeyer sold 2,400 shares of the firm’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $39.39, for a total transaction of $94,536.00. Following the completion of the sale, the director now owns 17,987 shares in the company, valued at $708,507.93. The disclosure for this sale can be found here. Company insiders own 3.75% of the company’s stock.
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.